Paper38899693
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Melani C and 35 others. N Engl J Med, 2024. Cited by 71 papers, by iCite.
Cite this record
ConductScience Library. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. Papers, record 38899693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38899693
- Disease
- diffuse large B-cell lymphoma301 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Clinical Trial, Phase I, Clinical Trial, Phase II, Research Support, N.I.H., Intramural
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Lenalidomide | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Piperidines | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Adenine | |
| Bridged Bicyclo Compounds, Heterocyclic | |
| Molecular Targeted Therapy | |
| Prednisone | |
| Progression-Free Survival | |
| Pyrazoles | |
| Pyrimidines | |
| Recurrence | |
| Sulfonamides |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z99 CA999999 | Intramural NIH HHS | United States | Z99CA999999 | PubMed | NIH RePORTER |
| ZIABC011006 | NIH | NIH RePORTER | |||
| ZIABC011772 | NIH | NIH RePORTER | |||
| ZIABC011780 | NIH | NIH RePORTER | |||
| ZIASC000550 | NIH | NIH RePORTER | |||
| ZIATR000047 | NIH | NIH RePORTER | |||
| ZICSC006536 | NIH | NIH RePORTER | |||
| ZICSC006537 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | Derived from the trial | Yes |
Source ClinicalTrials.gov
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35653592 | The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. | Blood | 2022 | https://conductscience.org/library/papers/35653592 | PubMed |
| 2 | 32289277 | A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32289277 | PubMed |
| 3 | 22885699 | Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. | Nature | 2012 | https://conductscience.org/library/papers/22885699 | PubMed |
| 4 | 28095146 | Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28095146 | PubMed |
| 5 | 31331917 | Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. | Blood | 2019 | https://conductscience.org/library/papers/31331917 | PubMed |
| 6 | 35717989 | Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. | Lancet | 2022 | https://conductscience.org/library/papers/35717989 | PubMed |
| 7 | 25842160 | Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25842160 | PubMed |
| 8 | 34516954 | Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34516954 | PubMed |
| 9 | 29713087 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. | Nat Med | 2018 | https://conductscience.org/library/papers/29713087 | PubMed |
| 10 | 28774879 | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. | Blood | 2017 | https://conductscience.org/library/papers/28774879 | PubMed |
| 11 | 21495023 | Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. | Cancer | 2011 | https://conductscience.org/library/papers/21495023 | PubMed |
| 12 | 26639348 | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. | N Engl J Med | 2016 | https://conductscience.org/library/papers/26639348 | PubMed |
| 13 | 38701792 | Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | https://conductscience.org/library/papers/38701792 | PubMed |
| 14 | 10676951 | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. | Nature | 2000 | https://conductscience.org/library/papers/10676951 | PubMed |
| 15 | 23045577 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23045577 | PubMed |
| 16 | 1406976 | Cooperative interaction between c-myc and bcl-2 proto-oncogenes. | Nature | 1992 | https://conductscience.org/library/papers/1406976 | PubMed |
| 17 | 28552327 | Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28552327 | PubMed |
| 18 | 29925955 | A multiprotein supercomplex controlling oncogenic signalling in lymphoma. | Nature | 2018 | https://conductscience.org/library/papers/29925955 | PubMed |
| 19 | 22698399 | Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22698399 | PubMed |
| 20 | 29641966 | Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29641966 | PubMed |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 71 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42972012 | The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma. | Leukemia | 2026 | https://conductscience.org/library/papers/42972012 | PubMed |
| 42851176 | [Clinical characteristics of acute thrombocytopenia in newly diagnosed follicular lymphoma patients receiving obinutuzumab chemotherapy]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | https://conductscience.org/library/papers/42851176 | PubMed |
| 42558624 | Targeting NOP14 remodels the tumor immune microenvironment and enhances the antitumor efficacy of PD-1 blockade in DLBCL. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558624 | PubMed |
| 42533058 | Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42533058 | PubMed |
| 42513315 | A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen. | J Clin Med | 2026 | https://conductscience.org/library/papers/42513315 | PubMed |
| 42487683 | Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes. | Annu Rev Cancer Biol | 2026 | https://conductscience.org/library/papers/42487683 | PubMed |
| 42439665 | Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy. | Cells | 2026 | https://conductscience.org/library/papers/42439665 | PubMed |
| 42409736 | [Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | https://conductscience.org/library/papers/42409736 | PubMed |
| 42284698 | Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring. | Blood Adv | 2026 | https://conductscience.org/library/papers/42284698 | PubMed |
| 42278551 | Molecular Insights and Novel Therapies for Lymphoproliferative Disorders. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278551 | PubMed |
| 42099680 | Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group. | Hemasphere | 2026 | https://conductscience.org/library/papers/42099680 | PubMed |
| 41824782 | Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma. | Blood Adv | 2026 | https://conductscience.org/library/papers/41824782 | PubMed |
| 41749954 | Lipid Metabolism Reprogramming in Diffuse Large B-Cell Lymphoma (DLBCL): Mechanisms and Treatment Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41749954 | PubMed |
| 41684587 | Bcl-2 inhibitor resistance in diffuse large b-cell lymphoma: establishing a prognostic signature and targeting alpha protein kinase 1. | Front Oncol | 2026 | https://conductscience.org/library/papers/41684587 | PubMed |
| 41657780 | Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41657780 | PubMed |
| 41654318 | 2026 Update on the Management of Diffuse Large B-Cell Lymphoma. | Am J Hematol | 2026 | https://conductscience.org/library/papers/41654318 | PubMed |
| 41591906 | RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41591906 | PubMed |
| 41556969 | Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability. | AIDS | 2026 | https://conductscience.org/library/papers/41556969 | PubMed |
| 41348035 | Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms? | Hematology Am Soc Hematol Educ Program | 2025 | https://conductscience.org/library/papers/41348035 | PubMed |
| 41310404 | The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/41310404 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| BCL6 | 604 | PubTator's text mining | https://conductscience.org/library/genes/604 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
Drugs5
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| OBINUTUZUMAB | CHEMBL1743048 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1743048 | ChEMBL |
| IBRUTINIB | CHEMBL1873475 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1873475 | ChEMBL |
| VENETOCLAX | CHEMBL3137309 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3137309 | ChEMBL |
| PREDNISONE | CHEMBL635 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL635 | ChEMBL |
| LENALIDOMIDE | CHEMBL848 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL848 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38899693
GET https://conductscience.org/api/papers/v1/38899693/authors?page=2